The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 12 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Walaliade: AI models outperform human physicians in top 2017 medical journals
“Two years ago, there weren't that many examples of prominent journals publishing AI and healthcare pieces where it was, you know, shown to work in healthcare context, and now it feels like every month there's a new nature paper or something coming out where, y…”
Walaliate: Genomics has few true healthcare applications 20 years after HGP
“We certainly haven't lived up to that, and in fact, it's been a little difficult to see exactly where genomics has had a true application today.”
Walaliyadde: The magical continuous diagnostic machine of the future is your bathroom
“I actually think the magical diagnostic machine of the future is your bathroom.”
Walaliyadde: Assurex generated $60M in revenue despite only 20% test reimbursement
“There's a company called Assurex in mental health. They were making sixty million dollars in revenue last year, but they were only getting 20% of their tests reimbursed.”
Walaliade: Hospitals are increasingly taking financial risk for patient care
“Hospitals are increasingly taking financial risk on their patients. They are financially on the hook for excessive care.”
Walaliade: Health plans demand cost-saving proof over product engagement
“Health insurance plans care a lot more about saving money than offering an engaging product and so for an early-stage startup, it's a lot harder for them to do the saving money piece, because that takes a long study to prove, and they do it eventually, but it'…”
Walaliyadde: One dominant company drove a decade of sequencing cost drops
“The dominant player in the sequencing machine space has almost entirely by itself been driving down the cost of sequencing over the last decade or so.”
Walaliyadde: Medicine lacks effective methods for early cancer detection and active diagnosis
“Risk tests just tell you your chance of getting cancer. They don't actually tell you if you have cancer right now, and so if you're at higher risk, that probably means you want to get tested more frequently, but we don't have good methods of testing and diagno…”
Walaliyadde: Single-payer systems like the UK will drive higher genomic test adoption
“In fact, I think in single-payer systems like the UK or outside, we might see much more adoption of some of these genomic tests.”
Walaliyadde: Non-invasive prenatal testing was the first genetic application and is saturated
“Non-invasive prenatal testing and infertility is one major area. In fact, that was the first. It was the first to make it big in genetics, and it's gotten a little saturated.”
Walaliyadde: Genomics splits into sequencing hardware like Intel and clinical applications
“And an easy way to think about genomics is there's a sequencing layer, which is the companies that make the sequencing machines like Illumina, which is like sort of Intel and chips. And then there's the application layer, which are companies that are using thi…”
Walaliyadde: Illumina expanded into the applications layer via Verinata, Grail, and Helix
“Lumina has started realizing that as well and is itself building applications. They bought a company called Verinata, which is a NIPT company... You know, they have a cancer company called Grail... There's a company called Helix. So they have started participa…”